AUS
NZ
UK
CA
USA
IND
Highlights
- Brainchip Holdings surges 10%, attracting attention after unexplained gains.
- Fortescue Metals sees a 2.5% rise, benefitting from a broader mining sector rally.
- Mesoblast shares rise 5%, boosted by FDA approval of its stem cell therapy.
The Australian stock market is off to a strong start in 2025, with the S&P/ASX 200 Index rising 0.4% to 8,192.9 points. Several individual stocks have shown notable performance today, with gains surpassing the broader market's growth. Below are three ASX shares that are climbing higher and the reasons behind their rises.
Brainchip Holdings Ltd (ASX:BRN)
Brainchip Holdings has seen its share price jump an impressive 10%, reaching 43 cents. The semiconductor company’s shares have been on a remarkable upward trajectory over the holiday period, despite the absence of any formal news. This surge in stock price has caught the attention of the Australian stock exchange operator, which issued a “speeding ticket” to investigate the unexplained gains. Brainchip was unable to provide an explanation for the surge, and it will be interesting to see if the price continues its climb once institutional investors return and the company releases its next quarterly update.
Fortescue Metals Group Ltd (ASX:FMG)
Shares in mining giant Fortescue Metals have gained 2.5%, reaching AU$18.72. The rise follows a broader rally in the materials sector, with many investors viewing mining stocks as oversold in 2024. This surge has contributed significantly to the overall positive performance of the ASX 200 Index. However, despite today’s gain, Fortescue shares remain down 36% compared to the same time last year, suggesting that the company is still in a recovery phase.
Mesoblast Ltd (ASX:MSB)
Biotechnology company Mesoblast has seen its share price rise by 5%, reaching AU$3.27. This surge follows the recent approval of its stem cell therapy, Ryoncil (remestemcel-L), by the US FDA. Ryoncil is now the first mesenchymal stromal cell (MSC) therapy approved in the United States and the only one approved for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in children aged two months and older. This major milestone has triggered strong investor interest, driving up the stock price as investors position themselves for the potential success of this treatment.
